European Patent Office gives approval to BioRestorative ThermoStem

A notice of allowance has been issued by the European Patent Office for a patent application related to BioRestorative Therapies Inc's BRTX metabolic ThermoStem program.

The notice of allowance was issued on February 6, 2023.

What Happened: Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose-derived stem cells.

The therapeutic combination of scaffolds as a delivery system and brown adipose-derived stem cells provides the ability to deliver metabolically active cells.

Why It Matters: The therapeutic benefits of using brown adipose have been demonstrated in various models. In Phase 1 and 2 clinical trials, some companies that use encapsulation technology coupled with cells have shown promising clinical results in treating type 1 diabetes.

Lance Alstodt, the company's CEO, said we are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes.

Price Action: BRTX shares were up 2.31% at $3.08 premarket on the last check Wednesday.